Is the Surge in Ampio Sustainable?
Ampio Pharmaceuticals made waves in the market on Tuesday morning and it looked like a day trader’s dream.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 246Why at Least One Analyst Isn’t Chasing Neogen
Neogen reported disappointing fiscal first-quarter financial results before the markets opened on Monday morning.
The Political Tweet That Thrashed the Biotech Sector
On Monday, a simple tweet from presidential candidate Hillary Clinton managed to wreck the biotech sector.
Edge Therapeutics Closes in on IPO With Updated Terms
Edge Therapeutics is offering more than 5 million shares in its initial public offering in an expected price range of $14 to $16 apiece.
NovoCure Gears Up for IPO
NovoCure has made an updated filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Why Warren Buffett Will Live to Be 90
courtesy of WhiteHouse.govActuaries preside over a weird science. Part of their jobs is to forecast how long people will live, or, on the other hand, when they will die. One set of figures stands…
Top 6 Biotech Movers From the Past Week
ThinkstockOver the past week, a few biotech companies made absolutely massive runs and some had serious falls. In the past year, the health care sector was on fire from positive trials, U.S. Food and…
Vascular Biogenics Rises on Presentation Hype
Vascular Biogenics was one of the leading stocks in the health care sector Friday, following news that the company will present at the European Society for Medical Oncology (ESMO) European Cancer Congress 2015.
Why Merrill Lynch Sees More Upside in Eli Lilly
Merrill Lynch reiterated a Buy rating and price objective on Eli Lilly after positive data on its Jardiance.
Penumbra IPO Soars After Pricing Above Range
Penumbra priced its initial public offering of 4 million shares at $30 per share on Thursday night, and the stock began trading Friday morning at $40.
Tracon Pharmaceuticals Surges With Positive Study
Tracon Pharmaceuticals made waves in the market on Friday morning, not so much due to one trial but really one patient who made all the difference.
Nabriva Sets Price for IPO
ThinkstockNabriva Therapeutics A.G. has filed an amended F-1 form with the U.S. Securities and Exchange Commission (SEC) regarding the anticipated price of its initial public offering (IPO) in the U.S. The previous filing set…
Why the Top Aerie Pharma Analyst Sees It Rising Even More
A Canaccord Genuity analyst has a Buy rating on Aerie Pharmaceuticals and increased the price target.
Can-Fite Makes a Comeback With New FDA Designation
Can-Fite BioPharma is building momentum with its most recent designation from the FDA.
Achillion Pharma Rises on Solid Interim Results
Its stock has suffered, but it is possible that Achillion’s interim trial results may have put the company back on the right track.